Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated small cell lung cancer (SCLC), according to results from the randomized Phase II DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World…
A medical laboratory scientist explains how laboratory investigations can support the early detection of colorectal cancer and why Nigerians should not ignore symptoms or be deterred by the cost and…
The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung…
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer…
